Clinical trials: Atopic Dermatitis (Eczema)
Pruritus, Atopic Dermatitis
Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus
Pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. Itching has a significant impact on the quality of life of AD sufferers, in particular night-time…
- Trial name
- NCT00838708
- Testing
- SRD174 Cream, vehicle cream
- Where
- 13 sites in United States
- Volunteers
- 62 people
- Sponsor
- Serentis Ltd.
Atopic Dermatitis
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male volunteers and Japanese participants with…
- Trial name
- NCT04211415
- Testing
- DS-2741a
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Start Up (NCT06461897)
- Testing
- Upadacitinib, Dupilumab
- Where
- 150 sites in United States, Argentina and 24 more
- Volunteers
- 699 people
- Sponsor
- AbbVie
Atopic Dermatitis
Therapist-guided vs Self-guided CBT for AD: Non-inferiority Trial
The study aims to test the hypothesized non-inferiority of a self-guided digital intervention compared to a therapist-guided variant for people with atopic dermatitis (AD).
- Trial name
- NCT05517850
- Testing
- Therapist-guided cognitive behavioral therapy administered online, Self-guided digital intervention based on cognitive behavioral therapy
- Where
- Sweden
- Volunteers
- 168 people
- Sponsor
- Karolinska Institutet
Mild to Moderate Atopic Dermatitis
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients
This study aims to evaluate the safety, tolerability and pharmacokinetic properties of IN-A002 Ointment in healthy adult male volunteers and mild to moderate atopic dermatitis patients
- Trial name
- NCT05729074
- Where
- South Korea
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Moderate-to-severe Atopic Dermatitis
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07211542
- Testing
- SHR-1905 Injection, SHR-1905 Injection Blank Preparation
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Dermatitis, Atopic
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy and safety of 611 in chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT05544591
- Testing
- 611 Q2W, 611 Q4W
- Where
- 5 sites in China
- Volunteers
- 93 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- NCT05158023
- Testing
- ASLAN004
- Where
- 83 sites in United States, Australia and 6 more
- Volunteers
- 302 people
- Sponsor
- ASLAN Pharmaceuticals
Atopic Dermatitis
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients
- Trial name
- NCT04369846
- Testing
- GM-XANTHO onitment
- Where
- 4 sites in Taiwan
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Xantho Biotechnology Co., LTD
Acne, Atopic Dermatitis
Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected.
- Conditions
- Acne, Atopic Dermatitis, Psoriasis Vulgaris, Rosacea
- Trial name
- NCT04472546
- Testing
- in-vivo mesure, Scotch, Lipid index
- Where
- France
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Study of TDM-180935 in Atopic Dermatitis Patients
Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients
- Trial name
- NCT06363461
- Testing
- TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Technoderma Medicines Inc.
Atopic Dermatitis
Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
The primary objective of the present multicentre, prospective, non-interventional study (NIS) is gathering knowledge on the actual use and effectiveness of Elidel® in Chinese patients with mild to moderate AD affecting sensitive…
- Trial name
- NCT04976868
- Testing
- Pimecrolimus 1% Top Cream
- Where
- 10 sites in China
- Volunteers
- 130 people
- Sponsor
- Mylan Inc.
Moderate to Severe Atopic Dermatitis
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD).
- Trial name
- NCT07558668
- Testing
- SYX-5219 Oral Capsule
- Where
- 14 sites in United States, Bulgaria and 4 more
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Sitryx Therapeutics Ltd
Moderate/Severe Atopic Dermatitis
Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis
To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.
- Trial name
- NCT01745159
- Testing
- tacrolimus
- Where
- 4 sites in China
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma China, Inc.
Atopic Dermatitis
A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical…
- Trial name
- NCT05387980
- Testing
- CIBINQO
- Where
- Japan
- Volunteers
- 1,128 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
Atopic dermatitis (AD), also known as eczema, is the most common inflammatory skin disorder of children, affecting 10-20% of children and 1-2% of adults.
- Trial name
- NCT01782703
- Where
- 4 sites in United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Atopic Dermatitis
Azithromycin in Atopic Dermatitis
The study will evaluate the role of adding azithromycin to topical treatment in patients with mild to moderate atopic dermatitis
- Trial name
- NCT07713186
- Testing
- Betamethasone or tacrolimus ointments, Azithromycin
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Atopic Dermatitis, Eczema, Atopic
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema.
- Trial name
- NCT07216027
- Testing
- PF-08049820
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 165 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema Herpeticum
Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis
Atopic Dermatitis (AD), also known as eczema, is a skin disease that causes the skin to be hot, dry and scaly, and have severe itching. There are different kinds of eczema.
- Trial name
- NCT00438022
- Where
- Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Primary Immunodeficiency, Psoriasis
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal.
- Conditions
- Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
- Trial name
- NCT04864886
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.